 Leap Therapeutics, Inc. NASDAQ:LPTX, a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of a public offering of 20,250,000 shares of common stock and pre-funded warrants to purchase up to 2,250,000 shares of its common stock. The gross proceeds to Leap from this offering were approximately 45 million, before deducting underwriting discounts and commissions and other offering expenses payable by Leap. 